Aldeyra Therapeutics, Inc. (ALDX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Aldeyra Therapeutics reported revenue of $0. Net income was -$33.8M, or -$0.56 per diluted share. Operating activities generated -$33.3M of cash. At fiscal year end, Aldeyra Therapeutics held $72.1M in total assets against $27.8M in total liabilities, including $70.0M of cash and equivalents.
Open the full interactive Aldeyra Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Aldeyra Therapeutics Key Stats
| Share Price | $0.90 |
|---|---|
| Market Cap | $54.3M |
| 52-Week Range | $0.90 – $5.66 |
| Shares Outstanding | 60.3 million (basic, 2026 Q2) |
Aldeyra Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$36.4M | -$56.2M | -$62.7M | -$42.8M | -$60.1M | -$35.3M |
| Pre-Tax Income | -$38.0M | -$57.8M | -$62.0M | -$37.5M | -$55.9M | -$33.8M |
| Income Tax | -$479,265 | $0 | $0 | $0 | $1,000 | $0 |
| Net Income | -$37.6M | -$57.8M | -$62.0M | -$37.5M | -$55.9M | -$33.8M |
| Diluted EPS | -$1.11 | -$1.07 | -$1.06 | -$0.64 | -$0.94 | -$0.56 |
Aldeyra Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$7.7M | -$6.5M | -$3.5M | -$5.5M |
| Diluted EPS | -$0.13 | -$0.11 | -$0.06 | -$0.09 |
Aldeyra Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $77.9M | $229.8M | $144.4M | — | $54.5M | $70.0M |
| Current Assets | $83.1M | $232.8M | $181.0M | $147.8M | $104.1M | $71.8M |
| Total Assets | $83.4M | $233.1M | $181.3M | $148.3M | $104.6M | $72.1M |
| Current Liabilities | $12.4M | $11.8M | $15.4M | $22.3M | $18.6M | $27.8M |
| Total Long-Term Debt | $16.0M | $16.0M | $15.8M | $15.3M | $15.0M | $15.3M |
| Total Liabilities | $23.8M | $27.4M | $30.3M | $28.5M | $33.6M | $27.8M |
| Shareholders' Equity | $59.5M | $205.7M | $151.0M | $119.8M | $71.0M | $44.3M |
Aldeyra Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$37.5M | -$42.6M | -$56.6M | -$30.3M | -$43.2M | -$33.3M |
| Cash From Investing | $29.0M | -$7,806 | -$30.0M | $30.0M | -$44.9M | $47.7M |
| Cash From Financing | $41.9M | $194.5M | $1.2M | -$1.3M | -$171,422 | $1.1M |
| Free Cash Flow | -$37.5M | -$42.6M | -$56.7M | -$30.3M | — | — |
Figures from Aldeyra Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Aldeyra Therapeutics financials page for every line item.
Aldeyra Therapeutics Company Profile
| Ticker | ALDX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Concord, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001341235 |
Frequently Asked Questions
What was Aldeyra Therapeutics' revenue in fiscal 2025?
Aldeyra Therapeutics (ALDX) reported revenue of $0 for fiscal 2025.
What is Aldeyra Therapeutics' annual revenue history?
Aldeyra Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Aldeyra Therapeutics' net income in fiscal 2025?
Aldeyra Therapeutics reported net income of -$33.8M for fiscal 2025.
What was Aldeyra Therapeutics' earnings per share (EPS) in fiscal 2025?
Aldeyra Therapeutics' diluted EPS was -$0.56 for fiscal 2025 (adjusted for any later stock splits).
What was Aldeyra Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Aldeyra Therapeutics reported revenue of $0.
How much debt does Aldeyra Therapeutics have?
Aldeyra Therapeutics reported $15.3M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Aldeyra Therapeutics are outstanding?
Aldeyra Therapeutics reported a weighted average of 60.3 million basic shares outstanding in 2026 Q2.
What is Aldeyra Therapeutics' market cap?
Based on its latest closing price, Aldeyra Therapeutics (ALDX) has a market capitalization of about $54.3M.
When does Aldeyra Therapeutics' fiscal year end?
Aldeyra Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Aldeyra Therapeutics headquartered?
Aldeyra Therapeutics lists its business address in Concord, Massachusetts in its SEC filings.